Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

Altri documenti

Y0000808

Sodium phenylbutyrate

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

4-PBA, 4-Phenylbutyric acid, 4-phenylbutyrate, Buphenyl, Sodium 4-phenylbutyrate, TriButyrate

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C10H11NaO2
Numero CAS:
1716-12-7
Peso molecolare:
186.18
Numero MDL:
MFCD00800247
Codice UNSPSC:
41116107
ID PubChem:
329831161
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

sodium phenylbutyrate

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

[Na+].[O-]C(=O)CCCc1ccccc1

InChI

1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
VPZRWNZGLKXFOE-UHFFFAOYSA-M

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Sodium phenylbutyrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Sodium phenylbutyrate is a histone deacetylase inhibitor.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Y0000809

Sodium phenylbutyrate impurity C, European Pharmacopoeia (EP) Reference Standard

1614512

Sodium phenylbutyrate, United States Pharmacopeia (USP) Reference Standard

1614556

Phenylbutyrate Related Compound B, United States Pharmacopeia (USP) Reference Standard

1614523

Phenylbutyrate Related Compound A, United States Pharmacopeia (USP) Reference Standard

1614534

Phenylbutyrate Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR3080

Phenylbutyrate Related Compound A, pharmaceutical secondary standard, certified reference material

PHR3081

Phenylbutyrate Related Compound B, pharmaceutical secondary standard, certified reference material

PHR3082

Phenylbutyrate Related Compound C, pharmaceutical secondary standard, certified reference material

PHR3237

Sodium Phenylbutyrate, pharmaceutical secondary standard, certified reference material

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?
A F List
Leukemia research, 22 Suppl 1, S7-11 (1998-09-12)
Viola Pomozi et al.
The Journal of investigative dermatology, 134(4), 946-953 (2013-12-20)
Mutations in the ABCC6 gene cause soft-tissue calcification in pseudoxanthoma elasticum (PXE) and, in some patients, generalized arterial calcification of infancy (GACI). PXE is characterized by late onset and progressive mineralization of elastic fibers in dermal, ocular, and cardiovascular tissues.
Sotaro Naoi et al.
The Journal of pediatrics, 164(5), 1219-1227 (2014-02-18)
To examine the effects of 4-phenylbutyrate (4PB) therapy in a patient with progressive familial intrahepatic cholestasis type 2. A homozygous c.3692G>A (p.R1231Q) mutation was identified in ABCB11. In vitro studies showed that this mutation decreased the cell-surface expression of bile
Elisabeth Kemter et al.
The Journal of biological chemistry, 289(15), 10715-10726 (2014-02-26)
Uromodulin (UMOD)-associated kidney disease (UAKD) belongs to the hereditary progressive ER storage diseases caused by maturation defects of mutant UMOD protein. Current treatments of UAKD patients are symptomatic and cannot prevent disease progression. Two in vitro studies reported a positive
Wei Zeng et al.
Life sciences, 103(1), 15-24 (2014-03-22)
Endoplasmic reticulum (ER) stress is involved in the pathogenesis of atherosclerosis (AS). Endothelial cell (EC) dysfunction and monocyte migration to the subendothelium are considered to be essential manifestations of AS. We conducted this study to determine whether ER stress was
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.